GuidelineClinical and molecular hepatology2012
KASL Clinical Practice Guidelines: Management of chronic hepatitis B.
Guideline in Clinical and molecular hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04724785 (Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.), which is not on this map. Cited by 85 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.Gut and liver · 2015Guideline
- 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.Korean journal of radiologyGuideline
- Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Trial
- Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.The Korean journal of internal medicine · 2017Trial
- Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).Clinical and molecular hepatology · 2016Trial
- Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition.PloS one · 2016Trial
- Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.Antimicrobial agents and chemotherapy · 2015Trial
- Trial
- Trial
- Factors associated with hepatitis B mother-to-child transmission in a national prevention program.Clinical and molecular hepatology · 2025Article
- [Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity.PloS one · 2024Article
- Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
- Platelet-to-White Blood Cell Ratio Is Associated with Adverse Outcomes in Cirrhotic Patients with Acute Deterioration.Journal of clinical medicine · 2022Article
- Changes in the Deceased-Donor Trend in Korea: Establishment of Regional Trauma Centers and KODA.Journal of clinical medicine · 2022Article
- Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.Hepatology international · 2021Article
- Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma.Gut and liver · 2021Article
- Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.Journal of Korean medical science · 2021Article
- Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review.PharmacoEconomics - open · 2020Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe guideline on the management of chronic hepatitis B (CHB) was first developed in 2004 and revised in 2007 by the Korean Association for the Study of the Liver (KASL). Since then there have been many developments, including the introduction of new antiviral agents and the publications of many novel research results from both Korea and other countries. In particular, a large amount of knowledge on antiviral resistance--which is a serious issue in Korea--has accumulated, which has led to new strategies being suggested. This prompted the new guideline discussed herein to be developed based on recent evidence and expert opinion. TARGET POPULATION: The main targets of this guideline comprise patients who are newly diagnosed with CHB and those who are followed or treated for known CHB. This guideline is also intended to provide guidance for the management of patients under the following special circumstances: malignancy, transplantation, dialysis, coinfection with other viruses, pregnancy, and children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.